Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer

BACKGRUOND: Since their first description, activating epidermal growth factor receptor (EGFR) mutations identify a distinct clinical entity of patients with non-small-cell lung cancer (NSCLC). FINDINGS: New targeted therapies for molecularly selected NSCLC are changing the natural history of the dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Stasi, Irene, Cappuzzo, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215821/
https://www.ncbi.nlm.nih.gov/pubmed/25505694
http://dx.doi.org/10.1186/2213-0802-2-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215821/
https://www.ncbi.nlm.nih.gov/pubmed/25505694
http://dx.doi.org/10.1186/2213-0802-2-2

Ejemplares similares